Gene-modified tumor cells as cellular vaccine

Cancer Immunology Immunotherapy

Volumn 43, Issue 3, 1996, Pages 165-173

  Baskar, Sivasubramanian ^a  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

Author keywords

costimulatory molecules; cytokines; gene modified tumor cells; major histocompatibility complex; protein transfer; tumor cell vaccine

Indexed keywords

CANCER VACCINE; CD86 ANTIGEN; CYTOKINE; TUMOR ANTIGEN;

CANCER IMMUNOTHERAPY; CONFERENCE PAPER; GENETIC ENGINEERING; GENETIC TRANSFECTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; CYTOKINES; GENE THERAPY; GENETIC VECTORS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOTHERAPY; LIPID BILAYERS; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; NEOPLASMS; PROTEINS; TRANSFECTION; UP-REGULATION;

EID: 0029853561     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050318     Document Type: Conference Paper

References (96)

1. Boon T, Cerottini JC, Van den Eynde B, Van der Bruggen P, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12: 337-365
2. Van den Eynde B, Brichard VG (1995) New tumor antigens recognized by T cells. Curr Opin Immunol 7: 674-681
3. Townsend A, Bodmer H (1989) Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 7: 601-624
4. Germain RN, Margulies D (1993) The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 11: 403-450
5. Kourilsky P, Jaulin C, Ley V (1991) The structure and function of MHC molecules. Possible implications for the control of tumor growth by MHC restricted T cells. Semin Cancer Biol 2: 275-282
6. Riethmuller G, Schneider-Gadicke E, Johnson JP (1993) Monoclonal antibodies in cancer therapy. Curr Opin Immunol 5: 732-739
7. Yeffenof E, Picker LJ, Scheuermann RH, Vitetta ES, Street NE, Tucker TF, Uhr JW (1993) Induction of B cell tumor dormancy by anti-idiotypic antibodies. Curr Opin Immunol 5: 740-744
8. Chapman PB, Houghton AN (1993) Non-antibody immunotherapy of cancer. Curr Opin Immunol 5: 726-731
9. Bierer BE, Sleckman BP, Ratnofsky SE, Burakoff SJ (1989) The biologic roles of CD2, CD4, and CD8 in T cell activation. Annu Rev Immunol 7: 579-599
10. Mueller DL, Jenkins MK, Schwartz RH (1989) Clonal expansion versus functional clonal inactivation: a costimulatory pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 7: 445-480
11. Rosenberg SA, Speiss P, Lafrenier R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318-1321
12. Klein E, Mantovani A (1993) Action of natural killer cells and macrophages in cancer. Curr Opin Immunol 5: 714-718
13. Rosenberg SA (1988) Immunotherapy of cancer using interleukin-2. Current status and future prospects. Immunol Today 9: 58-62
14. Russell S (1990) Lymphokine gene therapy for cancer. Immunol Today 11: 196-200
15. Blankenstein T, Rowley S, Schreiber H (1991) Cytokines and cancer: Experimental systems. Curr Opin Immunol 3: 694-698
16. Pardoll DM (1993) New strategies for enhancing the immunogenicity of tumors. Curr Opin Immunol 5: 719-725
17. Colombo M, Forni G (1994) Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 15: 48-51
18. Powell MB, Conta BS, Horowitz M, Ruddle NH (1985) The differential inhibitory effect of lymphotoxin and immune interferon on normal and malignant lymphoid cells. Lymphokine Res 4: 13-26
19. Old LJ (1985) Tumor necrosis factor (TNF). Science 230: 630-632
20. Tepper RI, Pattengale PK, Leder P (1989) Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57: 503-512
21. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E (1990) Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172: 1217-1224
22. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397-403
23. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffe LM, Karasuyama H, Baker M, Pardoll DM (1991) Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254: 713-716
24. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitzky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539-3543
25. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H (1994) Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264: 961-965
26. Tanaka K, Yoshioka T, Bieberich C, Gilbert J (1988) Role of the major histocompatibility complex class I antigens in tumor growth and metastasis. Annu Rev Immunol 6: 359-380
27. Hui K, Grosveld F, Festenstein H (1984) Rejection of transplantable AKR leukemic cells following MHC DNA-mediated cell transformation. Nature 311: 750-752
28. Wallich R, Bublic N, Hammerling G, Katzav S, Segal S, Feldman M (1985) Abrogation of metastatic properties of tumor cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315: 301-303
29. Hui K, Sim T, Foo T, Oei A (1989) Tumor rejection mediated by transfection with allogenic class I histocompatibility gene. J Immunol 143: 3835-3843
30. Ostrand-Rosenberg S, Garcia EP, Roby CA, Clements VK (1991) Influence of major histocompatibility complex class I, class II and TLA genes on tumor rejection. Semin Cancer Biol 2: 311-319
31. Bleiden TM, McAdam AJ, Frelinger JG, Lord EM (1991) Mechanism of cytolytic T lymphocyte killing of a low class I-expressing tumor. J Immunol 147: 1433-1438
32. Plautz GE, Yang Z, Wu B, Gao X, Huang L, Nabel GJ (1993) Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 90: 4645-4649
33. Kobayashi H (1979) Immunological xenogenization of tumor cells. GANN Monograph on Cancer Res 23
34. Ostrand-Rosenberg S, Thakur A, Clements VK (1990) Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol 144: 4068-4071
35. James RFL, Edwards S, Hui KM, Bassett PD, Grosveld F (1991) The effect of class II gene transfection on the tumorigenicity of the H-2k-negative mouse leukaemia cell line K36.16. Immunology 72: 213-218
36. Chen PW, Ananthaswamy HN (1993) Rejection of K1735 murine melanoma in syngenic hosts requires expression of majorhistocompatibility complex class I antigens and either class II antigens or interleukin-2. J Immunol 151: 244-255
37. Leach DR, Calaahan GN (1995) Fibrosarcoma cells expressing allogenic MHC class II antigens induce protective antitumor immunity. J Immunol 154: 738-743
38. Baskar S, Viola A, Marshall EG, Hughes E, Ostrand-Rosenberg S (1994) MHC class II transfected tumor cells induce long-term tumor-specific immunity in autologous mice. Cell Immunol 155: 123-133
39. Hock RA, Reynolds BD, Tucker-McClung CL, Kwok WW (1995) Human class II major histocompatibility complex gene transfer into murine neuroblastoma leads to loss of tumorigenicity, immunity against subsequent tumor challenge, and elimination of microscopic preestablished tumors. J Immunother 17: 12-18
40. Ostrand-Rosenberg S (1994) Tumor immunotherapy: the tumor cells as an antigen-presenting cell. Curr Opin Immunol 6: 722-727
41. + tumor cells. J Immunol 149: 2391-2396
42. Ostrand-Rosenberg S, Roby CA, Clements VK (1991) Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule. J Immunol 147: 2419-2422
43. Baskar S, Clements VK, Glimcher LH, Nabavi N, Ostrand-Rosenberg S (1996) Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules. J Immunol 156: 3821-3827
44. Nabavi N, Freeman GJ, Gault A, Godfrey D, Nadler LM, Glimcher LH (1992) Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature 360: 266-268
45. Schwartz RH (1992) Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71: 1065-1068
46. Chen L, Linsley PS, Hellstrom EK (1993) Costimulation of T cells for tumor immunity. Immunol Today 14: 483-486
47. Robey E, Allison JP (1995) T cell activation: integration of signals from the antigen receptor and costimulatory molecules. Immunol Today 16: 306-310
48. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP (1992) CD28-mediated signalling costimulates murine T cells and prevents anergy in T cell clones. Nature 356: 607-609
49. Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM (1993) Human T cell clonal anergy is induced by antigen presentation in the absence of B7 Costimulation. Proc Natl Acad Sci USA 90: 6586-6590
50. Linsley PS, Ledbetter JA (1993) The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 11: 191-212
51. Freeman GJ, Freeman AS, Segil JM, Lee G, Whitman JF, Nadler LM (1989) B7, A new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol 143: 2714-2722
52. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo Jr VA, Lombard LA, Gray GS, Nadler LM (1993) Cloning of B7-2: A CTLA-4 counter receptor that costimulates human T cell proliferation. Science 262: 909-911
53. Hathcock KS, Laszio G, Dickler HB, Bradshaw J, Linsley PS, Hodes RJ (1993) Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science 262: 905-907
54. Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL, Somoza C (1993) B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366: 76-79
55. Freeman GJ, Borriello F, Modes RJ, Reiser H, Gribben JG, Ng JW, Kim J, Goldberg JM, Kathcock KS, Laszlo G, Lombard LA, Wang S, Gray GS, Nadler LM, Sharpe AH (1993) Murine B7-2, an alternative CTLA-4 counter-receptor that costimulates T cell proliferation and interleukin-2 production. J Exp Med 178: 2185-2192
56. Gimmi CD, Freeman GJ, Gribben JG, Sugita K, Freedman AS, Morimoto C, Nadler LM (1991) B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin-2. Proc Natl Acad Sci USA 88: 6575-6579
57. + T cells. J Exp Med 173: 759-762
58. Martin PJ, Ledbetter JA, Morishita Y, June CH, Betty PG, Hansen JA (1986) A 44 kilodalton cell surface homodimer regulates interleukin-2 production by activated human T lymphocytes. J Immunol 136: 3282-3287
59. Thompson CB, Lindsten T, Ledbetter JA, Kunkel SL, Young HA, Emerson SG, Leiden JM, June CH (1989) CD28 activation pathway regulates the production of multiple T cell-derived lymphokines/cytokines. Proc Natl Acad Sci USA 86: 1333-1337
60. Reiser H, Freeman GJ, Razi-wolf Z, Gimmi CD, Benacerrat B, Nadler LM (1992) Murine B7 antigen provides an efficient costimulatory signal for the activation of murine T lymphocytes via the T-cell receptor/CD3 complex. Proc Natl Acad Sci USA 89: 271-275
61. Chen L, Ashe S, Brady W, Hellstrom I, Hellstrom K, Ledbetter J, McGowan P, Linsley P (1992) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71: 1093-1102
62. + T cells by B7-transfected melanoma cells. Science 259: 368-370
63. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH (1993) Constitutive expression of B7 restores the immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 90: 5687-5690
64. + T lymphocytes by B7, natural ligand for CD28 can be used to treat established mouse melanoma. J Immunol 153: 421-428
65. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I, Hellstrom EK (1994) Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 179: 523-532
66. Ramakrishnan L, Castle M, Wu Y, Liu Y (1994) T cell constimulation by B7/BB1 CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med 179: 1205-1214
67. Baskar S, Nabavi N, Glimcher LH, Ostrand-Rosenberg S (1993) Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunity. J Immunother 14: 209-215
68. Townsend SE, Su FW, Atherton JM, Allison JP (1994) Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res 54: 6477-6483
69. La Motte RN, Rubin MA, Barr E, Leiden JM, Bluestone JA, Mokyr MB (1996) Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule. Cancer Immunol Immunother 42: 161-169
70. Yang G, Hellstrom I, Hellstrom KE, Chen L (1995) Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J Immunol 154: 2794-2800
71. Gajewski TF, Fallarino F, Uyttenhove C, Boon T (1996) Tumor rejection requires a CTLA-4 ligand provided by the host or expressed on the tumor. J Immunol 156: 2909-2917
72. Matulonis U, Dosiou C, Freeman GJ, Lamont C, Mauch P, Nadler LM, Griffin JD (1996) B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. J Immunol 156: 1126-1131
73. Hathcock KS, Laszlo G, Pucillo C, Linsley PS, Hodes RJ (1994) Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med 180: 631-640
74. Thompson CB (1995) Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell 81: 979-982
75. Freeman GJ, Boussiotis VA, Anumanthan A, Berstein GM, Ke X-Y, Rennert PD, Gray GS, Gribben JG, Nadler LM (1995) B7-1 and B7-2 do not deliver identical costimulatory signals since B7-2 and not B7-1 costimulates the initial production of IL-4. Immunity 2: 523-532
76. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvill SS, Sobel RA, Weiner HL, Nabavi N, Glimcher LH (1995) B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80: 707-718
77. Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N, Herold KC, Bluestone JA (1995) Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 181: 1145-1155
78. Katz J, Benoist C, and Mathis D (1995) T helper subsets in insulin-dependent diabetes. Science 268: 1185-1188
79. Hodge JW, Abrams S, Scholm J, Kantor JA (1994) Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 54: 5552-5555
80. Bost KL, Bieligk SC, Jaffe BM (1995) Lymphokine mRNA expression by transplantable murine B lymphocytic malignancies: tumor derived IL-10 as a possible mechanism for modulating the antitumor response. J Immunol 154: 718-729
81. Mlzoguchi H, O'shea JJ, Longo DL, Loeffler CM, McVicar DM, Ochea AC (1992) Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258: 1795-1798
82. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 181: 619-629
83. Yang G, Hellstrom EK, Mizuno MT, Chen L (1995) In vitro priming of tumor-reactive cytotoxic T lymphocytes by combining IL-10 with B7-CD28 costimulation. J Immunol 155: 3897-3903
84. Coughlin CM, Wysocka M, Kurzawa HL, Lee WMF, Trinchieri G, Eck SL (1995) B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res 55: 4980-4987
85. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA (1994) CTLA-4 can function as a negative regulator of T cell activation. Immunity 1: 405-413
86. Krummel MF, Allison JP (1995) CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182: 459-465
87. Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734-1736
88. Wigler M, Silverstein S, Lee L, Pellicer A, Cheng Y, Axel R (1977) Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. Cell 11: 223-232
89. Moolten FL, Wells JM (1990) Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 82: 297-300
90. Moolten FL, Wells JM, Heyman RA, Evans RM (1990) Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Hum Gen Ther 1: 125-134
91. Gansbacher B, Rosenthal FM, Zier K (1993) Reteroviral vector-mediated cytokine-gene transfer into tumor cells. Cancer Invest 11: 345-354
92. Mulligan RG (1993) The basic science of gene therapy. Science 260: 926-931
93. Medof ME, Kinoshita T, Nussenzweig V (1984) Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 160: 1558-1578
94. McHugh RS, Ahmed SN, Wang Y, Sell KW, Selvaraj P (1995) Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc Natl Acad Sci USA 92: 8059-8063
95. Brunschwig EB, Levine E, Trefzer U, Tykocinski ML (1995) Glycosyl-phosphatidylinositol-modified murine B7-1 and B7-2 retain costimulator function. J Immunol 155: 5498-5505
96. Huang J, Getty RR, Chisari FV, Fowler P, Greenspan NS, Tykocinski ML (1994) Protein transfer of preformed MHC-peptide complexes sensatizes target cells to T cell cytolysis. Immunity 1: 607-613